Core Viewpoint - Oklo's subsidiary Atomic Alchemy has received its first materials license from the Nuclear Regulatory Commission (NRC), marking a significant milestone for the company and potentially shifting investor sentiment from bearish to bullish [1][4]. Group 1: NRC License Impact - The NRC license is a pivotal development for Oklo, validating its path toward commercial isotope production and allowing the company to handle and process isotopes at its Idaho Radiochemistry Laboratory [4]. - This approval opens up a secondary revenue stream in the medical and industrial isotope market, complementing Oklo's primary focus on Aurora power plants [4]. Group 2: Financial Performance and Outlook - Despite reporting a wider-than-expected per-share loss of $0.27 for Q4, the company maintains a strong financial position with over $1.1 billion in cash and equivalents, providing a multi-year runway for data center deployment [6]. - As of early 2026, Oklo has established an 18GW pipeline, attracting high-density users like Meta Platforms, which contributes to positive market sentiment [7]. Group 3: Market Sentiment and Analyst Ratings - Options traders are optimistic about Oklo's stock, with contracts indicating a potential price increase of about 30% over the next three months, setting an upper price target of approximately $70 [7]. - Wall Street analysts also share this optimism, with a consensus rating of "Moderate Buy" and a mean target price of about $108, suggesting nearly 80% upside potential [9].